Autoimmune dysautonomia evaluation, serum-994

Test info

  
Autoimmune dysautonomia evaluation, serum
  
994
  
LAB994
  
MSO
  
ANNA (Antineuronal Nuclear Antibody)
Anti-CV2
Anti-Enteric Neuronal Antibody
Anti-Hu
Antineuronal
Cerebellar Antibodies
Chorea
Collapsin Response-Mediator Protein-5 Antibody (CRMP-5), Serum
Cramp-fasciculation
CRMP-5, IgG
Dorsal Root Ganglion Antibody
DPPX
Hu Antibody
Isaac’s disease
Motor End-Plate Antibody
Motor Nerve Terminal Antibodies
Myoid Antibody
Neuromuscular hyperexcitability
Neuromyotonia
Neuronal ganglionic acetylcholine receptor antibody
Neuronal Nuclear Antibody Panel
Neuronal Potassium Channel Ab
Neuronal-Anti
Paraneoplastic Antibodies
Paraneoplastic Autoantibody Evaluation
Paraneoplastic Neurological Autoimmunity
Stiff-man Syndrome
Potassium Channel Antibodies
  
  • Investigating idiopathic dysautonomic symptoms
  • Directing a focused search for cancer in patients with idiopathic dysautonomia
  • Investigating autonomic symptoms that appear in the course or wake of cancer therapy and are not explainable by recurrent cancer or metastasis (detection of autoantibodies in this profile helps differentiate autoimmune dysautonomia from the effects of chemotherapy)

Specimen

  
  • For optimal antibody detection, specimen collection is recommended before initiation of immunosuppressant medication or intravenous immunoglobulin treatment.
  • This test should not be requested in patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given, and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held 1 week and assayed if sufficiently decayed, or canceled if radioactivity remains.
  • Patient should have no general anesthetic or muscle-relaxant medications in the previous 24 hours.
  
Serum
  
  
4.0 mL
  
2.5 mL
  

Immediately following collection, mix sample thoroughly by gentle inversion, 5 times

  
  1. Allow sample to clot for a minimum of 30 minutes
  2. Spin within two (2) hours of sample collection
  3. Transfer serum to a Screw cap transfer vial/tube (Mayo T914), labelled as serum
  
  
  
  1. Allow sample to clot
  2. Spin
  3. Transfer serum to a Screw cap transfer vial/tube (Mayo T914), labelled as serum, within two (2) hours of sample collection
  

Refrigerated (preferred) – 28 days

Ambient – 72 hours

Frozen – 28 days

  
28 days
  
  • Gross hemolysis
  • Gross lipemia
  • Gross icterus

Performance

  
Mayo Clinic Laboratories (DYS2): R-NX
  
Mo - Fr
  
10 days
  

Indirect Immunofluorescence (IFA)

Cell Binding Assay (CBA)

Western Blot (WB), Immunoblot (IB

Radioimmunoassay (RIA)

Clinical and Interpretive info

  

See report

  
Negative results do not exclude autoimmune dysautonomia or cancer.

Intravenous immunoglobulin (IVIg) treatment prior to the serum collection may cause a false-positive result.

Billing

  
83519
86255 x 6

Additional CPT codes (if appropriate):
86255 – AMPCS
86256 – AMPIS
86255 – AMPHS
84182 – AMIBS
84182 – AN1BS
84182 – AN2BS
84182 – CRMWS
86255 – DPPCS
86256 – DPPTS
86255 – GABCS
86256 – GABIS
86255 – NMDCS
86256 – NMDIS
84182 – PC1BS
84182 – PCTBS
86255 – PCABP
86255 – PCATR

Tracking

  
02/22/2022
  
02/24/2022